NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
NeOnc reported positive Phase 2a data for NEO100 in recurrent glioma, showing 48.9% six-month progression-free survival against a 20% benchmark with a p-value of 0.0047. Median overall survival was 26.09 months, and the company plans to request a Type B meeting with the FDA to discuss a potential registrational pathway.
Key figures
- Drug Name
- NEO100
- Phase Of Trial
- Phase 2a
- P value
- 0.0047
- Total patients
- 24
- Median os months
- 26.09
- Benchmark percent
- 20
- Patients on treatment
- 5
- Six month pfs percent
- 48.9
- Six month survival percent
- 86.7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.